In a clinical setting where tumor tissue is unavailable, comprehensive screening for all oncogenic mutations in both paralog genes GNAQ and GNA11 as well as in CYSLTR2 and PLCB4, would be necessary to improve the detection rate of tumor-derived DNA in ocular fluids. This evidence concerns the gene PLCB4 and neoplasm.